Quest Diagnostics has recently launched a groundbreaking prostate cancer test that aims to improve the diagnosis and grading of this disease.   This innovative lab service utilizes Envision Science's exclusive biomarkers and technology, with the ultimate goal of enhancing the accuracy of prostate cancer diagnosis and grading. The launch of this new test was announced by Quest Diagnostics, th..
ize innovative therapies for patients with cardiorenal diseases. Tenapanor is one such therapy, and its acceptance by China's Center for Drug Evaluation is a significant achievement for Ardelyx. With the NDA submission expected to be approved by the end of 2024, this marks a major milestone in bringing tenapanor to patients in China. Ardelyx CEO expresses gratitude towards collaboration partner ..
Akari Therapeutics, a late-stage biotechnology company, has provided updates on the development of its drug nomacopan for the treatment of pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company is making progress towards initiating a Phase 3 study of nomacopan in pediatric HSCT-TMA by the end of 2023. Furthermore, Akari plans to commence..
Nymox Pharmaceutical Corporation has recently made significant changes to its board of directors and management, while also rejecting a potential transaction that was deemed not beneficial for the company and its shareholders. As part of these changes, Mr. Randall Lanham, former in-house legal counsel, and Mr. Christopher Riley, former chief financial officer, have been terminated from their pos..
Sirona Biochem Provides Corporate Update   VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), a leading biotechnology company, is excited to share the latest developments with its shareholders.   Dear valued shareholders,   We are delighted to provide you with an update on the significant progress we have made over..
development capabilities, access new markets, and tap into the expertise of regional healthcare professionals. The partnership between Burjeel Holdings and BridgeBio Pharma is a prime example of this trend. By collaborating with local stakeholders in Abu Dhabi, they can leverage the advanced infrastructure and resources available in the Emirate to accelerate their research and development effort..
Direct Biologics LLC, a biotechnology company in the late stages of development, has recently published groundbreaking findings from their Phase 2 clinical trial in the prestigious Journal CHEST. The trial focused on evaluating the effectiveness of ExoFlo™, a regenerative medicine platform that utilizes extracellular vesicles (EVs) derived from bone marrow-derived mesenchymal stem cells (BM-MSCs..
Leap Therapeutics, a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced the initiation of Part B of the DeFianCe study for DKN-01 in colorectal cancer patients. This study aims to assess the effectiveness of Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, when combined with standard care bevacizumab and chemotherapy as a second-line treatment for advan..
